Information for readers
18 November 2016
18 November 2016
Jean‐François Dufour – 18 November 2016
Zoe Hall, Nicholas J. Bond, Tom Ashmore, Francis Sanders, Zsuzsanna Ament, Xinzhu Wang, Andrew J. Murray, Elena Bellafante, Sam Virtue, Antonio Vidal‐Puig, Michael Allison, Susan E. Davies, Albert Koulman, Michele Vacca, Julian L. Griffin – 18 November 2016 – Nonalcoholic fatty liver disease (NAFLD) can progress from simple steatosis (i.e., nonalcoholic fatty liver [NAFL]) to nonalcoholic steatohepatitis (NASH), cirrhosis, and cancer.
18 November 2016
Pierre L. Lévy, Sarah Duponchel, Hannah Eischeid, Jennifer Molle, Maud Michelet, Gaëlle Diserens, Martina Vermathen, Peter Vermathen, Jean‐Francois Dufour, Hans‐Peter Dienes, Hans‐Michael Steffen, Margarete Odenthal, Fabien Zoulim, Birke Bartosch – 18 November 2016 – Chronic infection with hepatitis C virus (HCV) is one of the main causes of hepatocellular carcinoma. However, the molecular mechanisms linking the infection to cancer development remain poorly understood.
18 November 2016
18 November 2016
Tatiana Kisseleva – 18 November 2016 – Liver fibrosis results from chronic liver injury of different etiologies. It is characterized by dysregulation of physiological remodeling, activation of myofibroblasts, and formation of a fibrous scar. Myofibroblasts develop contractile functions and secrete the extracellular matrix proteins that form this fibrous scar. Myofibroblasts are not present in the normal liver but activate and proliferate in response to injury and inflammation.
Tatehiro Kagawa, Yukihiko Adachi, Naoaki Hashimoto, Hiroshi Mitsui, Tomohiko Ohashi, Masashi Yoneda, Izumi Hasegawa, Shunji Hirose, Kota Tsuruya, Kazuya Anzai, Tetsuya Mine – 18 November 2016
Constantine J. Karvellas, Jaime L. Speiser, Mélanie Tremblay, William M. Lee, Christopher F. Rose, for the US Acute Liver Failure Study Group – 18 November 2016 – Acetaminophen (APAP)‐induced acute liver failure (ALF) is associated with significant mortality. Traditional prognostic scores lack sensitivity. Serum liver‐type fatty acid binding protein (FABP1) early (day 1) or late (day 3‐5) levels are associated with 21‐day mortality in the absence of liver transplant.